PHR1143

リシノプリル

Name: リシノプリル
Brand: SIAL

Pharmaceutical Secondary Standard; Certified Reference Material

別名:

(S)-1-[N2-(1-カルボキシ-3-フェニルプロピル)-リシル-プロリン二水和物, MK-521

ログインで組織・契約価格をご覧ください。

サイズを選択してください

この商品について

実験式（ヒル表記法）:

C₂₁H₃₁O₅N₃ · 2H₂O

CAS番号:

83915-83-7

分子量:

441.52

NACRES:

NA.24

PubChem Substance ID:

329823163

UNSPSC Code:

41116107

MDL number:

MFCD01698825

主要文書

すべての文書を表示

テクニカルサービス

お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。

お手伝いします

テクニカルサービス

お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。

お手伝いします

InChI

1S/C21H31N3O5.2H2O/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15;;/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29);2*1H2/t16-,17-,18-;;/m0../s1

SMILES string

[H]O[H].[H]O[H].NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O

InChI key

CZRQXSDBMCMPNJ-ZUIPZQNBSA-N

grade

certified reference material, pharmaceutical secondary standard

agency

traceable to Ph. Eur. L0702000, traceable to USP 1368609

API family

lisinopril

CofA

current certificate can be downloaded

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-30°C

Quality Level

300

Gene Information

human ... ACE(1636)

類似した製品をお探しですか？訪問製品比較ガイド

General description

Lisinopril is a lysine derivative of enalaprilat and belongs to the group of angiotensin converting enzyme (ACE) inhibitors. It is widely used as an orally active medication in the treatment of high blood pressure and may be used to treat congestive heart failure.

Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.

Application

Lisinopril may be used as a pharmaceutical reference standard for the quantification of the analyte in pharmaceutical formulations using kinetic spectrophotometric technique.

These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

Biochem/physiol Actions

アンギオテンシン変換酵素（ACE）阻害薬。

Analysis Note

このような2次標準は、USP、EP（PhEur）、BPの1次標準にマルチトレーサビリティを提供します。

Other Notes

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

To see an example of a Certificate of Analysis for this material enter LRAB3302 in the slot below. This is an example certificate only and may not be the lot that you receive.

Values of analytes vary lot to lot.

pictograms

GHS08

signalword

Danger

hcodes

H360D,H373

pcodes

P202 - P260 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Repr. 1A - STOT RE 2

target_organs

Kidney

保管分類

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

PHR1143-1G-PW: + PHR1143-1G:

jan

試験成績書（COA）

製品のロット番号・バッチ番号を入力して、試験成績書（COA）を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial.

Jason V Baker et al.

PloS one, 7(10), e46894-e46894 (2012-10-20)

Treatments that reduce inflammation and cardiovascular disease (CVD) risk among individuals with HIV infection receiving effective antiretroviral therapy (ART) are needed. We conducted a 2 × 2 factorial feasibility study of lisinopril (L) (10 mg daily) vs L-placebo in combination

Determination of lisinopril in pharmaceuticals by a kinetic spectrophotometric method

Cakar M and Popovic G

J. Serb. Chem. Soc., 77(10), 1437-1442 (2012)

Lisinopril

Lancaster GS and Todd AP

Drugs, 35(6), 646-669 (1988)

Proteinuria triggers renal lymphangiogenesis prior to the development of interstitial fibrosis.

Saleh Yazdani et al.

PloS one, 7(11), e50209-e50209 (2012-11-29)

Proteinuria is an important cause of progressive tubulo-interstitial damage. Whether proteinuria could trigger a renal lymphangiogenic response has not been established. Moreover, the temporal relationship between development of fibrosis, inflammation and lymphangiogenesis in chronic progressive kidney disease is not clear

Combined angiotensin inhibition for the treatment of diabetic nephropathy.

Linda F Fried et al.

The New England journal of medicine, 369(20), 1892-1903 (2013-11-12)

Combination therapy with angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) decreases proteinuria; however, its safety and effect on the progression of kidney disease are uncertain. Methods We provided losartan (at a dose of 100 mg per day) to patients with

リシノプリル

Pharmaceutical Secondary Standard; Certified Reference Material

サイズを選択してください

この商品について

主要文書

特性

InChI

SMILES string

InChI key

grade

agency

API family

CofA

technique(s)

application(s)

format

storage temp.

Quality Level

Gene Information

関連するカテゴリー

詳細

General description

Application

Biochem/physiol Actions

Analysis Note

Other Notes

安全性情報

pictograms

signalword

hcodes

pcodes

Hazard Classifications

target_organs

保管分類

wgk

flash_point_f

flash_point_c

適用法令

PHR1143-1G-PW: + PHR1143-1G:

資料

試験成績書（COA）

以前この製品を購入いただいたことがある場合

参考文献

テクニカルサービス